Royalty Report: Device, Medical, Delivery – Collection: 268269

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Device
  • Medical
  • Delivery
  • Therapeutic
  • cardiac
  • Surgical
  • Drugs
  • Catheter
  • Pain
  • Diagnostic
  • Drug Discovery
  • implants
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 268269

License Grant
Licensor will manufacture and supply the Implantable System for Remodulin, and Licensee will manufacture and supply Remodulin for use in the system. Each party will perform certain additional activities to support the commercialization of the Implantable System for Remodulin.
License Property
The system incorporates a proprietary Licensor intravascular infusion catheter with Medtronic’s SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH). We believe this technology has the potential to reduce many of the patient burdens and other complications associated with the use of external pumps to administer prostacyclin analogues.
Field of Use
The Parties wish to collaborate on the commercialization in the United States of the delivery of Remodulin® (treprostinil) injection drug to patients with pulmonary arterial hypertension using Medtronic implantable pumps, catheters, and programmers, and related Medtronic accessories.

IPSCIO Record ID: 180208

License Grant
The company entered into an agreement providing the company with exclusive rights in the United States and certain other countries to develop Licensors proprietary intravascular infusion catheter to be used with its SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH).
License Property
The proprietary intravascular infusion catheter is to be used with its SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of PAH.  The Implantable System for Remodulin will be exclusive to Remodulin so long as we purchase a minimum percentage of our annual requirement for implantable pump systems from Licensor.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 166205

License Grant
Licensor grants an exclusive worldwide license, with tile right to sub-license, under Licensors Product Intellectual Property to make, have made, sell, or have sold, and otherwise commercialize, market and distribute the Product throughout the world.
License Property
Licensor has developed a proprietary drug delivery system, including drug infusion pumps, ports, catheters, programming systems and accessories.  The Product is a preservative-free injectable formulation or formulations of clonidine and all current or future analogs, modifications and improvements of clonidine.

The SynchroMed system is the only externally programmable, implantable, drug infusion system available today. Using telemetry, the clinician can program its pump to deliver precise doses of medication at specific times to provide optimum therapy for each patient. It is widely used with morphine sulfate to block pain signals traveling to the brain and is also used to treat severe spasticity associated with multiple sclerosis, spinal cord injury, cerebral palsy, and traumatic brain injury. Clinical trials are expected to be initiated in 1998.

Field of Use
The Licensee will test the use of clonidine, delivered directly to the spinal fluid by the Medtronic SynchroMed(R) implantable drug infusion system, in the treatment of chronic intractable pain. Intractable pain is typically defined as constant, long-term pain that is not manageable without intervention. Clonidine delivered intrathecally (inside the sheath that surrounds the spinal cord) may be effective in patients with pain who no longer experience adequate relief with intrathecal morphine. These patients, if not already using a SynchroMed system, will require its implant to deliver intrathecal clonidine.

IPSCIO Record ID: 1850

License Grant
The Company entered into an agreement for the license for Epidural catheters used to infuse drugs into the epidural space in the spinal column (vi) Implantable infusion ports and pumps and their attached catheters used for drug therapy and access to the vascular system (vii) Intra-aortic balloon catheters (viii) Drainage catheters used to drain chest cavities, surgical incisions, wounds and abscesses.
Field of Use
Fields of Application)
(v) Epidural catheters used to infuse drugs into the epidural space in the spinal column.
(vi) Implantable infusion ports and pumps and their attached catheters used for drug therapy and access to the vascular system.
(vii) Intra-aortic balloon catheters.
(viii) Drainage catheters used to drain chest cavities, surgical incisions, wounds and abscesses.

IPSCIO Record ID: 27452

License Grant
The Licensor hereby grants to the Company the perpetual, fully paid and irrevocable right and license (hereinafter referred to as the 'License') to (I) exclusively (1) manufacture, assemble, produce, sell and distribute to Customers in the Territory, and (2) cause to be manufactured, assembled, produced, sold and distributed to Customers in the Territory by one or more Affiliates or sublicensees of the Company as it may from time to time select, the Pump Components excluding, however, the manufacture, production, or assembly of the Spring Assemblies.

The Company has the exclusive U.S. marketing rights and license for an ambulatory infusion–a round, spring-driven infusion pump with dedicated administration sets and related accessories which also includes an electronic alarm to denote the completion of an infusion.

License Property
SideKick Infusion System — a round, spring-driven infusion pump with dedicated administration sets and related accessories; (ii) the Paragon Infusion System — a round, spring-driven infusion pump with dedicated administration sets and related accessories; and (iii) the Paragon elite Infusion System –a round, spring-driven infusion pump with dedicated administration sets and related accessories which also includes an electronic alarm to denote the completion of an infusion.
Field of Use
The companion product SIDEKICK utilizes a patented spring technology to deliver IV antibiotics over a shorter time period.

IPSCIO Record ID: 1804

License Grant
The Company hereby grants the worldwide right to manufacture, cause to be manufactured, promote, sell, market, distribute and use the Pump Technology; programmable implantable insulin pump system.
License Property
Implantable microinfusion pump systems intended for in vivo use; utilizes Pump Technology for diabetes or non-diabetes applications. Glucose Controllers, Glucose Monitors, Long-Term Glucose Sensors and the abdominal lead that connects the implantable pump to a Long-Term Glucose Sensor are not Licensed Products.  An apparatus or system which utilizes Glucose Sensing Technology to control an insulin infusion device in a human or in an animal.   Any monitor product utilizing Glucose Sensing Technology to provide indications of glucose concentration or changes in glucose concentration in a human or in an animal.

IPSCIO Record ID: 28235

License Grant
The Amendment expands the scope of the Licensee's license from the Licensor. Under the Cross-License Amendment, the Licensee will continue to develop the pulse program in the field of cardiopulmonary disease.
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices.

INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.

The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.

Field of Use
The Licensee will develop its Licensor pulse program for the treatment of three additional cardiopulmonary diseases chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness.

IPSCIO Record ID: 49323

License Grant
The parties wish to amend certain provisions of the Supply Agreement to, among other things, change the pricing terms; and the parties wish to amend certain provisions of the License Agreement to, among other things, add royalty terms, as additional consideration for the Products to be supplied under the Supply Agreement.
License Property
INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD.  The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 28439

License Grant
The Licensor, government organization, desires to transfer inventions to the private sector through commercialization Licenses to facilitate the commercial development of products and processes for public use and benefit.  The Licensor granted a nonexclusive License under the Licensed Patent Rights in the United States of America including its Territories, Commonwealths and Possessions to use and have used the Licensed Process to administer Drug to treat gliomas. Licensee does not have the right to subLicense.
License Property
U.S. Patent 5,720,720 Convection-Enhanced Drug Delivery including 1L13-PE38QQR, for treating gliomas delivered or recommended to be delivered using the Licensed Process.
Field of Use
Licensed Fields of Use Nonexclusive for using the Licensed Process to administer Drug to treat gliomas.

IPSCIO Record ID: 294293

License Grant
Licensor grants an exclusive, worldwide license under the Licensor IP Rights, Licensor Research IP Rights, and Licensors rights under the Joint Research IP Rights to develop, make, have made, use, offer for sale, sell, have sold, export and import the Product for use in the Field.
License Property
The Product shall mean a biodegradable, preformed, macroscopic implant device consisting of the Active Agent, as the sole active pharmaceutical ingredient, incorporated into the Delivery Matrix.

The joint research is for Implants for the treatment of dopamine associated states, meaning Biodegradable implant containing a dopamine modluating compound.

Licensor patents include Methods for manufacturing delivery systems and systems, and, Modulating burst and release profiles from coestruded implants by treating implant ends, and, Influencing drug release  profiles from implants by selectively adjusting the location and amount of drug loading, and, Implant devices that differ by release profile and methods of making and using same.

Field of Use
Parties have been collaborating since on the development of a biodegradable sustained release formulation of an approved dopamine agonist. The result is Licensee’s NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from Parkinson’s disease without motor response complications. NP201 leverages Licensee’s long-acting delivery (LAD™) technology and Licensee’s proprietary biodegradable polymer matrix implant technology to achieve optimal drug release over an extended period of time.

IPSCIO Record ID: 4994

License Grant
The Company has an exclusively license for patents and a patent application for the composition and production of the stable prostacyclin analog now known as UT-15 for the treatment of pulmonary hypertension and congestive heart failure and for late-stage peripheral vascular disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.